Merck & Co. CapEx decreased by 4.1% to $991.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.4%, from $1.33B to $991.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a -1.9% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $986.00M | $1.17B | $1.21B | $984.00M | $1.13B | $1.13B | $1.15B | $1.01B | $965.00M | $902.00M | $989.00M | $861.00M | $791.00M | $783.00M | $937.00M | $1.33B | $764.00M | $987.00M | $1.03B | $991.00M |
| QoQ Change | — | +18.9% | +3.1% | -18.5% | +14.7% | -0.3% | +2.0% | -12.4% | -4.2% | -6.5% | +9.6% | -12.9% | -8.1% | -1.0% | +19.7% | +41.7% | -42.5% | +29.2% | +4.7% | -4.1% |
| YoY Change | — | — | — | — | +14.5% | -3.9% | -4.9% | +2.3% | -14.5% | -19.9% | -13.9% | -14.5% | -18.0% | -13.2% | -5.3% | +54.2% | -3.4% | +26.1% | +10.2% | -25.4% |